Cell-El. The ASD, Bio-marker, Stem Cell Connection
Cell-El research of diagnostic bio-markers is unraveling the mysterious cause of Autism Spectrum Disorder (ASD) and paving the way for promising stem cell therapy.
Your child’s participation in Cell-El’s successful clinical diagnostic study of young children is paving the way to targeted effective therapy.
Cell-El delves beyond the behavioral observation of ASD to its underlying biological mechanisms. Our diagnostic findings provide the rationale for targeted treatments. Stem cell treatments have been successful and received clinical approval for many similar conditions.
The Cell-El team and its multi-national clinical collaborations which have approvals from the Helsinki ethics committees and the Israeli Ministry of Health.
- Dr. Gesundheit brings his scientific and clinical experience from The Hospital for Sick Children, Toronto, Canada, the department of Pediatric Hematology-Oncology at Soroka Hospital Beer Sheva, Israel and Hadassah Hospital, Jerusalem Israel to his methodical research in ASD and its immunological aspects as well as to the rationale for the treatment with stem cells.
BENI GESUNDHEIT, MD PhD
Dr. Ellis has 35 years of senior management experience for R&D companies – large, medium, small, startup and incubators. His development and project leadership skills have brought therapeutics to the clinic and to market.
Ronald Ellis, PhD MBA
Mrs. Hochbaum has over 20 years of experience working with families of children with ASD. She speaks with parents and clinicians about our ASD diagnostic study, thereby enabling our research. Speak with Leah if you want to join our team and work together at solving the autism challenge!
LEAH HOCHBAUM, MA OTR/L
Dr. Zisman has over ten years of experience in the fields of biotechnology, biochemistry, cell biology, immunology, and bioassays. He is responsible for laboratory issues, assay development and immunology.
Philip David Zisman, PhD
Dr. Posen brings over ten years of medical and scientific writing experience with academic researchers and with the pharmaceutical and medical device industries. At Cell-El, she works on preparation of clinical trial-related documents and manuscripts for publication.
Yehudit Posen, PhD
- Dr. Lisovoder has 15 years of experience in biotechnology and in drug development, clinical and pre-clinical studies where she leads international collaboration. She is the director of the Galilee Research Administration and a leading promoter of biotechnological accelerator.
Nadya Lisovoder, MD
Mr. Labinsky has extensive experience and planning in working with companies in business, corporate and investment management. Baruch is licensed by the Israel Securities Authority as an investment portfolio manager.
Baruch Labinsky, MA
Mrs. Suna has over 20 years of web design and development experience with small to large organizations as well as pharmaceutical companies. Susan works closely with the team crafting the website and its messaging.
Susan Suna, MA
Cell-El’s research shows an important association between the immune system and ASD. These findings are the basis for targeted treatments. For more information please read our Diagnostics page.
The entire procedure takes less than an hour. It involves:
- Signing a consent form
- Filling out a medical questionnaire with a team member
- Drawing about 5 ml venous blood
- The child does not have to fast
The diagnostic test involves drawing about 5 cc of venous blood and this standard procedure has minimal risk.
Cell-El’s team has been researching the connection between ASD, immune dysfunction and stem cells for more than five years. We have published our research and submitted protocols to international regulatory authorities.
Cell-El plans on launching a therapeutic study in 2019. Please fill in the form below to receive updates.
Cell-El diagnostic and future therapy study criteria
- Male and female children
- age 2-12
- Diagnosed autism spectrum disorder (ASD) according to Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV (299.00) or DSM-V (299.00).
- Informed consent signed by the parents
- All children that have been treated with systemic steroids or have undergone immune suppression treatment over the last 6 months.
- All children diagnosed with severe infectious diseases or sepsis over the last 6 months.
- All children diagnosed with mild infectious diseases (including common cold, ear infection, etc.) over the last month
- Children with ASD treated for a severe convulsive disorder.
- Children with hematological or malignant disorders.
Read our research and peer reviewed articles.